| Literature DB >> 30992461 |
Kiyono Sekii1, Shunta Yorimoto1, Hikaru Okamoto1, Nanna Nagao1, Takanobu Maezawa2, Yasuhisa Matsui3, Katsushi Yamaguchi4, Ryohei Furukawa5,6, Shuji Shigenobu7,8, Kazuya Kobayashi9.
Abstract
Many flatworms can alternate between asexual and sexual reproduction. This is a powerful reproductive strategy enabling them to benefit from the features of the two reproductive modes, namely, rapid multiplication and genetic shuffling. The two reproductive modes are enabled by the presence of pluripotent adult stem cells (neoblasts), by generating any type of tissue in the asexual mode, and producing and maintaining germ cells in the sexual mode. In the current study, RNA sequencing (RNA-seq) was used to compare the transcriptomes of two phenotypes of the planarian Dugesia ryukyuensis: an asexual OH strain and an experimentally sexualized OH strain. Pathway enrichment analysis revealed striking differences in amino acid metabolism in the two worm types. Further, the analysis identified serotonin as a new bioactive substance that induced the planarian ovary de novo in a postembryonic manner. These findings suggest that different metabolic states and physiological conditions evoked by sex-inducing substances likely modulate stem cell behavior, depending on their different function in the asexual and sexual reproductive modes. The combination of RNA-seq and a feeding assay in D. ryukyuensis is a powerful tool for studying the alternation of reproductive modes, disentangling the relationship between gene expression and chemical signaling molecules.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30992461 PMCID: PMC6467871 DOI: 10.1038/s41598-019-42025-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Five stages of sexualization in the planarian D. ryukyuensis. The worm begins to develop reproductive organs upon switching from the asexual to the sexual state. The process can be roughly divided into five stages based on the development of reproductive organs[14]. Briefly, the asexual worm possesses the ovarian primordia (op); the ovary (ov), with an increasing number of oogonia, starts to form during stage 1; the maturing ovaries with developing oocytes form during stage 2; the primordial testis (te), primordial yolk glands (yg)[35], and copulatory apparatus (ca) form during stage 3; the genital pore (gp) becomes externally apparent during stage 4; the worm becomes sexually mature, ready for mating, and egg laying during stage 5. Note that the planarian body size changes because of the feeding procedure used for sexualization[10]: if the food does not contain sex-inducing substances, asexual worms become bigger without gonad development.
Top 40 asexual and sexual DEGs. The DEGs are presented in descending order of log2FC; log2FC (asexual/sexual) for the asexual DEGs, and log2FC (sexual/asexual) for the sexual DEGs. Bold font indicates DEGs chosen for experimental validation by whole-mount in situ hybridization and qRT-PCR (DEG identification criteria: likelihood ratio test, FDR < 0.01).
| Sexuality | ID | Length | logFC | logCPM | Likelihood ratio | FDR | Sequence description | |
|---|---|---|---|---|---|---|---|---|
| Asexual |
| 1736 | 7.77E + 00 | 1.12E + 00 | 6.77E + 01 | 1.88E - 16 | 8.77E - 15 | NA |
| TR47241|c4_g2_i8 | 439 | 7.38E + 00 | −2.18E - 01 | 3.04E + 01 | 3.45E - 08 | 9.94E - 07 | NA | |
| TR46139|c4_g2_i1 | 666 | 7.17E + 00 | −3.83E - 01 | 1.63E + 01 | 5.42E - 05 | 1.05E - 03 | NA | |
|
| 1857 | 6.94E + 00 | 6.87E - 01 | 3.47E + 01 | 3.88E - 09 | 1.21E - 07 | NA | |
|
| 1025 | 6.94E + 00 | −1.13E - 01 | 3.99E + 01 | 2.67E - 10 | 9.05E - 09 | NA | |
|
| 1621 | 6.48E + 00 | −3.47E - 01 | 3.71E + 01 | 1.11E - 09 | 3.60E - 08 | NA | |
| TR38806|c0_g1_i14 | 1721 | 6.40E + 00 | −8.75E - 01 | 1.33E + 01 | 2.59E - 04 | 4.38E - 03 | NA | |
| TR30470|c0_g3_i1 | 248 | 6.38E + 00 | −9.94E - 01 | 1.75E + 01 | 2.80E - 05 | 5.68E - 04 | NA | |
|
| 1259 | 6.36E + 00 | 3.92E - 01 | 2.59E + 01 | 3.66E - 07 | 9.55E - 06 | NA | |
| TR3030|c0_g1_i1 | 718 | 6.32E + 00 | −1.07E + 00 | 2.12E + 01 | 4.18E - 06 | 9.54E - 05 | ubiquitin-conjugating enzyme e2 k | |
| TR42765|c0_g1_i1 | 959 | 6.30E + 00 | −8.67E - 01 | 1.31E + 01 | 3.03E - 04 | 5.05E - 03 | NA | |
| TR46277|c2_g2_i1 | 533 | 6.26E + 00 | 1.91E - 01 | 2.24E + 01 | 2.18E - 06 | 5.16E - 05 | tnf receptor-associated factor 6 | |
| TR44416|c0_g2_i1 | 331 | 6.22E + 00 | −1.20E + 00 | 2.53E + 01 | 4.83E - 07 | 1.24E - 05 | NA | |
| TR46530|c0_g1_i3 | 1531 | 6.20E + 00 | −9.00E - 01 | 1.21E + 01 | 5.00E - 04 | 7.91E - 03 | NA | |
| TR47833|c9_g1_i1 | 227 | 6.18E + 00 | −1.24E + 00 | 1.58E + 01 | 7.11E - 05 | 1.35E - 03 | NA | |
| TR46881|c0_g1_i3 | 1303 | 6.11E + 00 | −1.28E + 00 | 1.47E + 01 | 1.28E - 04 | 2.30E - 03 | NA | |
| TR32727|c0_g2_i1 | 649 | 6.09E + 00 | −1.27E + 00 | 1.93E + 01 | 1.13E - 05 | 2.43E - 04 | NA | |
|
| 853 | 6.03E + 00 | −1.31E - 01 | 3.53E + 01 | 2.76E - 09 | 8.68E - 08 | NA | |
| TR16992|c0_g1_i1 | 573 | 5.88E + 00 | −1.37E + 00 | 1.71E + 01 | 3.57E - 05 | 7.10E - 04 | NA | |
|
| 3272 | 5.82E + 00 | 4.80E - 01 | 5.02E + 01 | 1.36E - 12 | 5.28E - 11 | ras-related protein m-ras-like | |
| TR12695|c0_g1_i1 | 265 | 5.73E + 00 | −1.46E + 00 | 1.39E + 01 | 1.92E - 04 | 3.35E - 03 | NA | |
| TR38469|c1_g1_i1 | 599 | 5.73E + 00 | −1.44E + 00 | 1.34E + 01 | 2.52E - 04 | 4.27E - 03 | NA | |
| TR45705|c0_g1_i6 | 671 | 5.71E + 00 | −1.41E + 00 | 1.18E + 01 | 5.84E - 04 | 9.10E - 03 | NA | |
| TR46364|c2_g10_i3 | 707 | 5.71E + 00 | −6.67E - 01 | 1.53E + 01 | 9.02E - 05 | 1.67E - 03 | NA | |
| TR39276|c0_g2_i1 | 607 | 5.69E + 00 | −1.39E + 00 | 1.70E + 01 | 3.79E - 05 | 7.52E - 04 | NA | |
| TR41905|c0_g1_i6 | 1664 | 5.65E + 00 | −1.60E + 00 | 1.28E + 01 | 3.53E - 04 | 5.80E - 03 | NA | |
| TR45986|c10_g2_i2 | 1597 | 5.65E + 00 | −1.24E + 00 | 1.86E + 01 | 1.60E - 05 | 3.38E - 04 | NA | |
| TR33991|c0_g4_i3 | 427 | 5.65E + 00 | −7.46E - 01 | 1.17E + 01 | 6.28E - 04 | 9.69E - 03 | NA | |
| TR49422|c3_g3_i1 | 241 | 5.62E + 00 | −1.49E + 00 | 1.58E + 01 | 6.88E - 05 | 1.30E - 03 | NA | |
| TR5159|c0_g1_i1 | 1479 | 5.62E + 00 | −4.16E - 01 | 2.92E + 01 | 6.52E - 08 | 1.83E - 06 | NA | |
| TR47359|c4_g3_i2 | 667 | 5.59E + 00 | −1.51E + 00 | 1.53E + 01 | 9.30E - 05 | 1.72E - 03 | NA | |
| TR35175|c0_g2_i1 | 644 | 5.59E + 00 | −6.89E - 01 | 1.74E + 01 | 3.09E - 05 | 6.22E - 04 | NA | |
| TR49328|c1_g5_i2 | 2038 | 5.54E + 00 | −1.32E + 00 | 1.48E + 01 | 1.20E - 04 | 2.17E - 03 | histone-lysine n-methyltransferase setmar-like | |
| TR46269|c0_g3_i1 | 308 | 5.54E + 00 | −1.48E + 00 | 1.95E + 01 | 1.02E - 05 | 2.20E - 04 | NA | |
| TR41950|c1_g1_i2 | 609 | 5.50E + 00 | −1.42E + 00 | 1.53E + 01 | 9.39E - 05 | 1.74E - 03 | NA | |
| TR45263|c0_g1_i3 | 2117 | 5.39E + 00 | −4.90E - 01 | 2.85E + 01 | 9.52E - 08 | 2.64E - 06 | NA | |
| TR49456|c5_g1_i2 | 365 | 5.38E + 00 | −1.79E + 00 | 1.51E + 01 | 1.01E - 04 | 1.85E - 03 | NA | |
| TR48894|c0_g6_i1 | 235 | 5.37E + 00 | −1.79E + 00 | 1.17E + 01 | 6.17E - 04 | 9.53E - 03 | NA | |
| TR48635|c1_g2_i5 | 268 | 5.31E + 00 | −1.84E + 00 | 1.20E + 01 | 5.34E - 04 | 8.39E - 03 | hypothetical protein TcasGA2_TC012988 | |
| TR48833|c5_g2_i3 | 256 | 5.31E + 00 | −1.68E + 00 | 1.23E + 01 | 4.65E - 04 | 7.41E - 03 | peptidoglycan recognition protein-1 | |
| Sexual | TR45015|c11_g2_i1 | 389 | 1.74E + 01 | 9.47E + 00 | 3.36E + 02 | 4.38E - 75 | 7.26E - 73 | NA |
| TR39624|c0_g1_i5 | 416 | 1.58E + 01 | 7.93E + 00 | 3.30E + 02 | 1.02E - 73 | 1.65E - 71 | NA | |
|
| 1604 | 1.52E + 01 | 7.27E + 00 | 8.10E + 02 | 3.47E - 178 | 2.33E - 174 | erythrocyte membrane associated protein | |
| TR79276|c0_g1_i1 | 1255 | 1.48E + 01 | 6.88E + 00 | 8.48E + 02 | 1.87E - 186 | 2.61E - 182 | sjchgc04698 protein | |
|
| 1916 | 1.47E + 01 | 6.77E + 00 | 7.97E + 02 | 2.87E - 175 | 1.62E - 171 | t-complex protein 1 subunit gamma-like | |
|
| 2089 | 1.47E + 01 | 6.74E + 00 | 8.51E + 02 | 3.44E - 187 | 5.68E - 183 | phosphoglycerate kinase 1 | |
|
| 2081 | 1.46E + 01 | 6.63E + 00 | 8.07E + 02 | 1.44E - 177 | 9.03E - 174 | tubulin alpha chain | |
|
| 347 | 1.45E + 01 | 8.10E + 00 | 3.72E + 02 | 6.74E - 83 | 1.27E - 80 | NA | |
| TR30631|c1_g2_i1 | 376 | 1.45E + 01 | 6.54E + 00 | 6.76E + 02 | 6.13E - 149 | 5.82E - 146 | NA | |
|
| 1798 | 1.44E + 01 | 6.45E + 00 | 7.55E + 02 | 3.23E - 166 | 8.36E - 163 | tubulin beta chain | |
| TR73196|c0_g1_i1 | 515 | 1.43E + 01 | 6.37E + 00 | 7.18E + 02 | 4.13E - 158 | 6.41E - 155 | NA | |
| TR39208|c0_g1_i2 | 428 | 1.43E + 01 | 6.34E + 00 | 4.83E + 02 | 4.92E - 107 | 1.49E - 104 | NA | |
|
| 627 | 1.43E + 01 | 6.33E + 00 | 7.76E + 02 | 7.21E - 171 | 2.78E - 167 | NA | |
| TR45486|c6_g3_i4 | 1107 | 1.42E + 01 | 7.85E + 00 | 9.12E + 02 | 2.16E - 200 | 7.85E - 196 | tubulin beta-4b partial | |
| TR73406|c0_g1_i1 | 881 | 1.41E + 01 | 6.13E + 00 | 8.31E + 02 | 9.67E - 183 | 9.23E - 179 | hypothetical protein | |
| TR18645|c0_g1_i1 | 1341 | 1.41E + 01 | 6.09E + 00 | 7.83E + 02 | 2.43E - 172 | 1.10E - 168 | NA | |
| TR39624|c0_g1_i3 | 2365 | 1.40E + 01 | 1.06E + 01 | 2.90E + 02 | 5.91E - 65 | 8.35E - 63 | NA | |
|
| 1639 | 1.40E + 01 | 6.03E + 00 | 7.36E + 02 | 3.95E - 162 | 7.46E - 159 | oxalate:formate antiporter | |
|
| 728 | 1.40E + 01 | 6.01E + 00 | 7.10E + 02 | 1.78E - 156 | 2.43E - 153 | glutathione s-transferase-like | |
|
| 814 | 1.39E + 01 | 5.95E + 00 | 7.09E + 02 | 3.59E - 156 | 4.86E - 153 | thioredoxin domain-containing protein 9 | |
| TR55853|c0_g1_i1 | 1079 | 1.39E + 01 | 5.94E + 00 | 6.91E + 02 | 2.17E - 152 | 2.43E - 149 | NA | |
| TR25043|c0_g1_i1 | 1156 | 1.39E + 01 | 5.93E + 00 | 7.07E + 02 | 9.55E - 156 | 1.28E - 152 | NA | |
| TR33142|c0_g1_i1 | 885 | 1.39E + 01 | 5.92E + 00 | 6.77E + 02 | 2.45E - 149 | 2.39E - 146 | expressed conserved protein | |
| TR18521|c0_g1_i2 | 272 | 1.39E + 01 | 5.91E + 00 | 7.15E + 02 | 1.75E - 157 | 2.52E - 154 | NA | |
| TR29388|c0_g2_i1 | 447 | 1.38E + 01 | 5.88E + 00 | 4.07E + 02 | 2.03E - 90 | 4.44E - 88 | NA | |
|
| 1831 | 1.38E + 01 | 5.82E + 00 | 6.15E + 02 | 1.07E - 135 | 6.36E - 133 | tubulin alpha-8 chain isoform x1 | |
| Sexual |
| 1199 | 1.37E + 01 | 5.76E + 00 | 6.99E + 02 | 5.28E - 154 | 6.42E - 151 | acyl- thioesterase |
|
| 3229 | 1.37E + 01 | 5.73E + 00 | 7.63E + 02 | 7.34E - 168 | 1.99E - 164 | NA | |
| TR29267|c1_g1_i1 | 680 | 1.37E + 01 | 5.70E + 00 | 6.18E + 02 | 1.74E - 136 | 1.06E - 133 | NA | |
|
| 668 | 1.36E + 01 | 5.67E + 00 | 6.81E + 02 | 3.16E - 150 | 3.27E - 147 | NA | |
|
| 1694 | 1.36E + 01 | 5.66E + 00 | 6.26E + 02 | 3.47E - 138 | 2.26E - 135 | hypothetical protein T265_14384, partial | |
|
| 2422 | 1.36E + 01 | 5.66E + 00 | 7.67E + 02 | 7.74E - 169 | 2.26E - 165 | kelch-like protein 10 | |
|
| 888 | 1.36E + 01 | 5.65E + 00 | 8.30E + 02 | 1.36E - 182 | 1.17E - 178 | NA | |
|
| 1281 | 1.36E + 01 | 5.63E + 00 | 6.10E + 02 | 1.23E - 134 | 7.17E - 132 | upf0565 protein c2orf69 homolog | |
|
| 822 | 1.36E + 01 | 5.62E + 00 | 5.97E + 02 | 9.13E - 132 | 4.92E - 129 | bcl-2-like protein 1 | |
| TR3479|c0_g1_i1 | 1295 | 1.35E + 01 | 5.56E + 00 | 6.78E + 02 | 1.89E - 149 | 1.86E - 146 | cysteine and histidine-rich protein 1 | |
| TR31160|c0_g1_i1 | 516 | 1.35E + 01 | 1.09E + 01 | 2.94E + 02 | 8.19E - 66 | 1.18E - 63 | NA | |
|
| 386 | 1.35E + 01 | 8.47E + 00 | 4.35E + 02 | 1.24E - 96 | 3.10E - 94 | NA | |
|
| 661 | 1.35E + 01 | 9.03E + 00 | 2.40E + 02 | 3.73E - 54 | 4.34E - 52 | NA | |
| TR38673|c1_g1_i1 | 1708 | 1.35E + 01 | 8.76E + 00 | 5.90E + 02 | 2.60E - 130 | 1.33E - 127 | NA |
Figure 2Qualitative and quantitative validation of sexual DEGs. Representative whole-mount in situ hybridization patterns for the ventral and dorsal sides of worms are shown. The expression pattern was judged based on three replicates. Signals were seen as blue/purple staining. The qRT-PCR data are shown relative to the expression level in the sexual worm, and log2 (relative expression) on the vertical axis indicates -ΔΔCt. Each circle indicates an individual asexual or sexual worm. Five replicates were used, but data are not shown if the expression was too low to be detected (handled as NA). The bars in the plots indicate the averages of -ΔΔCt. Asterisks indicate significant differences between the asexual and sexual worms (Student’s or Welch’s t-test: *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant). Ph, pharynx.
KEGG pathway enrichment analysis of asexual and sexual DEGs. Pathways indicated in bold represent amino acid metabolism pathways (DEG identification criteria: likelihood ratio test, FDR < 0.01).
| Sexuality | Pathway | Fold enrichment | FDR | |
|---|---|---|---|---|
| Asexual |
| 237.1 | 4.18E - 11 | 3.13E - 09 |
|
| 334.4 | 1.07E - 09 | 4.02E - 08 | |
|
| 204.6 | 9.37E - 07 | 2.34E - 05 | |
|
| 165.6 | 1.83E - 06 | 3.42E - 05 | |
| mmu04080:Neuroactive ligand-receptor interaction | 77.3 | 1.91E - 05 | 2.87E - 04 | |
| mmu04810:Regulation of actin cytoskeleton | 75.6 | 2.04E - 05 | 2.55E - 04 | |
| mmu04510:Focal adhesion | 75.6 | 2.04E - 05 | 2.55E - 04 | |
|
| 326.0 | 3.53E - 05 | 3.78E - 04 | |
| mmu04514:Cell adhesion molecules (CAMs) | 289.8 | 4.53E - 05 | 4.25E - 04 | |
| mmu00620:Pyruvate metabolism | 237.1 | 6.92E - 05 | 5.76E - 04 | |
|
| 200.6 | 9.80E - 05 | 7.35E - 04 | |
| mmu05200:Pathways in cancer | 43.5 | 1.08E - 04 | 7.33E - 04 | |
| mmu05217:Basal cell carcinoma | 173.9 | 1.32E - 04 | 8.23E - 04 | |
|
| 163.0 | 1.50E - 04 | 8.67E - 04 | |
| mmu00564:Glycerophospholipid metabolism | 144.9 | 1.91E - 04 | 1.03E - 03 | |
| mmu04666:Fc gamma R-mediated phagocytosis | 124.2 | 2.62E - 04 | 1.31E - 03 | |
| mmu04916:Melanogenesis | 113.4 | 3.15E - 04 | 1.48E - 03 | |
| mmu04270:Vascular smooth muscle contraction | 93.1 | 4.70E - 04 | 2.07E - 03 | |
| mmu04310:Wnt signaling pathway | 84.1 | 5.76E - 04 | 2.40E - 03 | |
| Sexual | mmu04120:Ubiquitin mediated proteolysis | 103.4 | 6.77E - 37 | 9.55E - 35 |
| mmu00230:Purine metabolism | 94.5 | 3.49E - 29 | 2.46E - 27 | |
| mmu04110:Cell cycle | 122.4 | 6.71E - 28 | 3.16E - 26 | |
| mmu05200:Pathways in cancer | 63.6 | 2.62E - 27 | 9.23E - 26 | |
| mmu03030:DNA replication | 165.8 | 1.47E - 24 | 4.14E - 23 | |
| mmu03430:Mismatch repair | 226.6 | 1.16E - 22 | 2.73E - 21 | |
| mmu04114:Oocyte meiosis | 140.9 | 1.03E - 17 | 2.07E - 16 | |
| mmu03440:Homologous recombination | 172.2 | 9.45E - 17 | 2.00E - 15 | |
| mmu04914:Progesterone-mediated oocyte maturation | 153.0 | 3.00E - 14 | 4.70E - 13 | |
| mmu03420:Nucleotide excision repair | 92.7 | 4.74E - 14 | 6.68E - 13 | |
| mmu00240:Pyrimidine metabolism | 60.9 | 7.30E - 14 | 9.35E - 13 | |
|
| 110.3 | 2.95E - 11 | 3.47E - 10 | |
| mmu03018:RNA degradation | 64.9 | 3.51E - 11 | 3.81E - 10 | |
| mmu00052:Galactose metabolism | 200.8 | 3.77E - 11 | 3.79E - 10 | |
| mmu00970:Aminoacyl-tRNA biosynthesis | 81.5 | 2.36E - 10 | 2.22E - 09 | |
| mmu04612:Antigen processing and presentation | 114.8 | 1.32E - 09 | 1.17E - 08 | |
| mmu03040:Spliceosome | 27.4 | 1.60E - 09 | 1.33E - 08 | |
| mmu00520:Amino sugar and nucleotide sugar metabolism | 107.1 | 1.98E - 09 | 1.55E - 08 | |
| mmu04622:RIG-I-like receptor signaling pathway | 95.6 | 1.81E - 07 | 1.34E - 06 | |
| mmu03410:Base excision repair | 89.3 | 2.46E - 07 | 1.73E - 06 | |
|
| 63.8 | 1.06E - 06 | 7.11E - 06 | |
| mmu05211:Renal cell carcinoma | 60.9 | 1.29E - 06 | 8.27E - 06 | |
| mmu00510:N-Glycan biosynthesis | 60.9 | 1.29E - 06 | 8.27E - 06 | |
| mmu04144:Endocytosis | 30.3 | 1.68E - 06 | 1.03E - 05 | |
|
| 133.9 | 2.80E - 06 | 1.64E - 05 | |
| mmu00500:Starch and sucrose metabolism | 133.9 | 2.80E - 06 | 1.64E - 05 | |
| mmu04910:Insulin signaling pathway | 49.6 | 3.05E - 06 | 1.72E - 05 | |
| mmu04310:Wnt signaling pathway | 43.2 | 5.41E - 06 | 2.93E - 05 | |
| mmu03050:Proteasome | 39.4 | 7.90E - 06 | 4.12E - 05 | |
| mmu00010:Glycolysis / Gluconeogenesis | 97.4 | 8.18E - 06 | 4.12E - 05 | |
| mmu04142:Lysosome | 35.2 | 1.24E - 05 | 6.04E - 05 | |
| mmu02010:ABC transporters | 82.4 | 1.41E - 05 | 6.63E - 05 | |
| mmu04540:Gap junction | 51.0 | 6.42E - 05 | 2.92E - 04 | |
| mmu05213:Endometrial cancer | 48.7 | 7.41E - 05 | 3.26E - 04 | |
| mmu04916:Melanogenesis | 46.6 | 8.50E - 05 | 3.63E - 04 | |
| mmu05210:Colorectal cancer | 44.6 | 9.68E - 05 | 4.02E - 04 | |
| mmu04912:GnRH signaling pathway | 41.2 | 1.24E - 04 | 4.98E - 04 | |
| mmu01040:Biosynthesis of unsaturated fatty acids | 160.7 | 1.37E - 04 | 5.35E - 04 | |
| Sexual | mmu04062:Chemokine signaling pathway | 36.9 | 1.72E - 04 | 6.57E - 04 |
| mmu00903:Limonene and pinene degradation | 133.9 | 2.04E - 04 | 7.58E - 04 | |
| mmu05340:Primary immunodeficiency | 133.9 | 2.04E - 04 | 7.58E - 04 | |
| mmu04020:Calcium signaling pathway | 34.6 | 2.11E - 04 | 7.63E - 04 | |
| mmu05016:Huntington’s disease | 17.2 | 2.14E - 04 | 7.53E - 04 | |
|
| 100.4 | 3.80E - 04 | 1.30E - 03 | |
| mmu04115:p53 signaling pathway | 80.3 | 6.07E - 04 | 2.04E - 03 | |
| mmu00983:Drug metabolism | 80.3 | 6.07E - 04 | 2.04E - 03 | |
| mmu04810:Regulation of actin cytoskeleton | 23.3 | 6.84E - 04 | 2.24E - 03 | |
|
| 73.0 | 7.40E - 04 | 2.37E - 03 | |
| mmu00620:Pyruvate metabolism | 73.0 | 7.40E - 04 | 2.37E - 03 | |
| mmu04630:Jak-STAT signaling pathway | 66.9 | 8.86E - 04 | 2.77E - 03 | |
| mmu00640:Propanoate metabolism | 66.9 | 8.86E - 04 | 2.77E - 03 | |
| mmu05212:Pancreatic cancer | 61.8 | 1.04E - 03 | 3.20E - 03 | |
| mmu05012:Parkinson’s disease | 19.1 | 1.22E - 03 | 3.64E - 03 | |
| mmu00480:Glutathione metabolism | 53.6 | 1.40E - 03 | 4.10E - 03 | |
| mmu05014:Amyotrophic lateral sclerosis (ALS) | 50.2 | 1.60E - 03 | 4.58E - 03 | |
| mmu05414:Dilated cardiomyopathy | 42.3 | 2.26E - 03 | 6.35E - 03 | |
| mmu03022:Basal transcription factors | 42.3 | 2.26E - 03 | 6.35E - 03 | |
| mmu03020:RNA polymerase | 40.2 | 2.50E - 03 | 6.90E - 03 | |
| mmu05222:Small cell lung cancer | 40.2 | 2.50E - 03 | 6.90E - 03 | |
| mmu04012:ErbB signaling pathway | 36.5 | 3.03E - 03 | 8.18E - 03 | |
|
| 36.5 | 3.03E - 03 | 8.18E - 03 | |
|
| 33.5 | 3.60E - 03 | 9.54E - 03 |
Figure 3KEGG pathway mapping of the tryptophan metabolism. Annotated genes in RNA-seq analysis were mapped against KEGG pathway maps (www.kegg.jp/kegg/kegg1.html)[26–28] using a KEGG mapper tool (http://www.kegg.jp/kegg/tool/map_pathway2.html). Genes identified as asexual DEGs are indicated in cyan, and genes identified as sexual DEGs are indicated in pink. A gene with three different isoforms that were identified as both asexual and sexual DEGs is indicated in green; specifically, TR48106|c0_g2_i2 is an asexual DEG; and TR35961|c1_g1_i1 and TR35961|c1_g1_i2 are sexual DEGs. Note that TR35961|c1_g1_i1 and TR35961|c1_g1_i2 were not distinguishable by qRT-PCR because the difference in length is only 33 bp, and thus these are shown as one gene. Genes not identified as DEGs but expressed in the planarian transcriptome in the present study are indicated in gray. The qRT-PCR data for each DEG are shown relative to the expression level in the sexual worm, and log2 (relative expression) on the vertical axis indicates -ΔΔCt. Each circle indicates an individual asexual or sexual worm. Eight to ten replicates were used, but data are not shown if the expression was too low to be detected or in the case of outliers (handled as NA). The bars in the plots indicate the averages of -ΔΔCt. Asterisks indicate significant differences between the asexual and sexual worms (Student’s or Welch’s t-test: *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant). Note that TR42512, which encodes tryptophanyl-tRNA synthase, is not shown on the present map because it was mapped to the KEGG pathway of “aminoacyl-tRNA biosynthesis”, but the results of qRT-PCR are shown on the bottom right.
DEGs in the KEGG pathways enriched both in asexual and sexual worms, with different sets of genes contributing to the enrichment score. Pathways indicated in bold are amino acid metabolism pathways (DEG identification criteria: likelihood ratio test, FDR < 0.01).
| Pathway | Asexual | Sexual | ||
|---|---|---|---|---|
| Count | KEGG gene name | Count | KEGG gene name | |
|
| 6 | CTH, DAO, DLD, DMGDH, PHGDH, TDH | 3 | AGXT2, GNMT, PSPH |
|
| 4 | ACMSD, DDC, KMO, TDO2 | 7 | ABP1, ALDH9A1, CAT, DDC, HADHA, KYNU, WARS |
|
| 4 | ACY1, CPS1, DAO, GOT1 | 5 | ABP1, ACY1, ALDH9A1, AMD1, SRM |
| mmu04810:Regulation of actin cytoskeleton | 4 | GSN, ITGAV, MYLK, WAS | 4 | APC2, ENAH, IQGAP1, PXN |
|
| 3 | DDC, GOT1, HPD | 3 | DDC, PAH, PRDX6 |
| mmu00620:Pyruvate metabolism | 3 | DLD, GRHPR, LDHD | 3 | ALDH9A1, MDH1, ME2 |
| mmu05200:Pathways in cancer | 4 | AXIN2, FZD4, ITGAV, WNT4 | 19 | APC2, ARNT, BCL2L1, BRCA2, CASP8, CBL, CCDC6, CDH1, CUL2, MLH1, MSH2, MSH6, PIAS1, RAD51, RBX1, SLC2A1, SUFU, TCEB1, TRAF3 |
| mmu04916:Melanogenesis | 3 | FZD4, TYR, WNT4 | 4 | ADCY1, ADCY2, ADCY5, TYR |
| mmu04310:Wnt signaling pathway | 3 | AXIN2, FZD4, WNT4 | 5 | APC2, CACYBP, CSNK2B, RBX1, RUVBL1 |
Insulin signaling and mTOR signaling pathways enriched when sexual DEGs were identified using strict (likelihood ratio test, FDR < 0.01) and relaxed (likelihood ratio test, FDR < 0.05) statistical criteria.
| Criteria for DEG identification | Sexuality | Pathway | Count | KEGG gene name | Fold enrichment | FDR | |
|---|---|---|---|---|---|---|---|
| FDR < 0.01 | Sexual | mmu04910:Insulin signaling pathway | 5 | CBL, EIF4E, EIF4EBP1, ELK1, G6PC | 49.6 | 3.05E-06 | 1.72E-05 |
| FDR < 0.05 | Sexual | mmu04910:Insulin signaling pathway | 5 | CBL, EIF4E, EIF4EBP1, ELK1, G6PC | 41.1 | 6.40E-06 | 3.09E-05 |
| Sexual | mmu04150:mTOR signaling pathway | 4 | CAB39, EIF4B, EIF4E, EIF4EBP1 | 88.9 | 1.05E-05 | 4.89E-05 |
Figure 4Serotonin is an ovary-inducing substance. (A) Images of the worms after 3 weeks of serotonin feeding. Induced ovaries (arrowhead) can be observed in the serotonin-fed groups but not in the control group. (B) Percentage of worms that developed externally observable ovaries (arrowhead in A) is shown (Fisher’s exact test: ***P < 0.001). Scoring was done at the completion of 4 weeks of serotonin feeding. Sample sizes were n = 60 for the control group; n = 59 for the group fed a low serotonin concentration (1.2 ng/worm/d); n = 53 for the group fed an intermediate serotonin concentration (12 ng/worm/d); and n = 64 for the group fed a high serotonin concentration (120 ng/worm/d). (C–H) The control, serotonin-fed, and experimentally sexualized worms were sagittally sectioned and stained with HE. The dorsal sides are at the top and the anterior sides are at the left. Only an ovarian primordium was found in the control worm (C), while ovaries were found in the serotonin-fed (D) and sexual worms (E). The cells indicated by the yellow arrow are an oocyte. The ovary of the serotonin-fed worm included an oocyte (D′, high magnification of the yellow box, dotted line) and a few dividing cells in a different part of that ovary (F, black arrow), as characterized by the nuclei with clumped chromatin darkly stained with HE. Neither the control (G) nor serotonin-fed (H) worms formed a testis or yolk gland, while these organs were found in the sexual worm (I). Domains bounded by the red line, the blue line, and the orange line are the female germ cell masses (ovaries), the male germ cell masses (testes), and yolk glands, respectively. op, ovarian primordium; ov, ovary; sov, supernumerary ovary; te, testis; yg, yolk gland; in, intestine. (J–L) The induction of other reproductive organs was examined by qRT-PCR analysis using the germ cell marker gene Dr-nanos (J), the testis marker gene DrY1 (K), and the yolk gland marker gene Dryg (L). The qRT-PCR data for each DEG are shown relative to the expression level in the control worm, and log2 (relative expression) on the vertical axis indicates -ΔΔCt. Each circle indicates an individual worm in the control or serotonin-fed groups. Eight replicates were used, but data are not shown if the expression was too low to be detected or in the case of outliers (handled as NA). The bars in the plots indicate the averages of -ΔΔCt. Asterisks indicate significant differences between the asexual and sexual worms (Tukey’s HSD test: *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant). Note that DrY1 and Dryg were detected in the control (asexual) group due to the high sensitivity of qRT-PCR, but neither the testis nor the yolk glands were morphologically observed in the asexual worms.